Analysts expect that Seelos Therapeutics Inc (NASDAQ:SEEL) will post earnings per share (EPS) of ($0.12) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Seelos Therapeutics’ earnings. Seelos Therapeutics posted earnings per share of ($3.60) during the same quarter last year, which would indicate a positive year-over-year growth rate of 96.7%. The company is expected to announce its next earnings report on Wednesday, October 30th.
On average, analysts expect that Seelos Therapeutics will report full-year earnings of ($3.83) per share for the current year, with EPS estimates ranging from ($4.30) to ($3.36). For the next financial year, analysts expect that the business will post earnings of ($0.97) per share, with EPS estimates ranging from ($0.99) to ($0.95). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Seelos Therapeutics.
Seelos Therapeutics (NASDAQ:SEEL) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04.
Several large investors have recently made changes to their positions in SEEL. Northern Trust Corp bought a new position in shares of Seelos Therapeutics in the second quarter worth about $25,000. Citadel Advisors LLC bought a new position in shares of Seelos Therapeutics in the second quarter worth about $29,000. Wedbush Securities Inc. bought a new position in Seelos Therapeutics during the second quarter valued at about $35,000. Ardsley Advisory Partners LP increased its stake in Seelos Therapeutics by 25.0% during the second quarter. Ardsley Advisory Partners LP now owns 50,000 shares of the company’s stock valued at $110,000 after acquiring an additional 10,000 shares during the period. Finally, A.R.T. Advisors LLC increased its stake in Seelos Therapeutics by 371.5% during the second quarter. A.R.T. Advisors LLC now owns 52,342 shares of the company’s stock valued at $115,000 after acquiring an additional 41,242 shares during the period. 11.91% of the stock is owned by institutional investors.
Shares of NASDAQ:SEEL remained flat at $$0.86 on Thursday. The company’s stock had a trading volume of 2,333 shares, compared to its average volume of 383,724. Seelos Therapeutics has a 12 month low of $0.86 and a 12 month high of $12.90. The stock has a fifty day moving average of $1.20.
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
Read More: Why Net Income is Important to Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.